UroGen Pharma Ltd. (URGN)
Sector: Healthcare
Industry: Pharmaceutical Preparations
Country: Israel
Exchange: NASDAQ
Market cap: $2.11B
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Latest financial period: June 30, 2026
Filed with the SEC: August 5, 2026
Estimated earnings date: November 5, 2026
Profit #1456 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROA | -49.3% | -56.0% | -60.3% | -60.6% |
Growth #422 of 1484 companies
Payout #1117 of 1484 companies
Safety #1479 of 1484 companies
Price #1425 of 1484 companies
